Difference between revisions of "Avatrombopag (Doptelet)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Immune thrombocytopenic purpura (ITP) medications" to "Category:Autoimmune thrombocytopenic purpura (ITP) medications") |
||
| Line 20: | Line 20: | ||
[[Category:Megakaryocyte growth factors]] | [[Category:Megakaryocyte growth factors]] | ||
| − | [[Category: | + | [[Category:Autoimmune thrombocytopenic purpura (ITP) medications]] |
[[Category:Drugs FDA approved in 2018]] | [[Category:Drugs FDA approved in 2018]] | ||
Revision as of 21:31, 14 June 2018
Mechanism of action
Thrombopoietin receptor agonist
Diseases for which it is used
- Bussel JB, Kuter DJ, Aledort LM, Kessler CM, Cuker A, Pendergrass KB, Tang S, McIntosh J. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014 Jun 19;123(25):3887-94. Epub 2014 May 6. link to original article PubMed
History of changes in FDA indication
- 5/21/2018: FDA approved "for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure."
Also known as
- Code names: E5501, YM477, AKR 501
- Brand name: Doptelet